Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge
Viruses · 17.02.2025 · 17 (2) · 277
DOI: 10.3390/v17020277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 17.02.2025. Verfasst von Gerald K Chege und 10 weiteren Autor:innen. Beteiligte Einrichtung: Primate Unit and Delft Animal Centre, Centre and Platform Office, South African Medical Research Council, Parrow Valley, Cape Town 7505, South Africa. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, AIDS Vaccines, HIV-1, Simian Immunodeficiency Virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African Medical Research Council with funds received from the South African Department of Science and Innovation. PLM is supported by the South African R…, South African Medical Research Council, South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation.
Abstract (Originalsprache)
We previously reported on HIV vaccines that elicited autologous Tier 2 neutralizing antibodies (nAbs) in rabbits. In the current study, we sought to establish a proof of concept that HIV vaccines using identical designs elicit Tier 2 nAbs in arhesus macaque (RM) model. DNA and MVA vaccines expressing SIV Gag and HIV-1 Env antigens were constructed, and in vitro expression was confirmed. A soluble envelope protein (gp140 Env) was expressed from a stable HEK293 cell line and purified using lectin affinity and size exclusion chromatography. The expression and secretion of SIV Gag and HIV-1 Env by the DNA and MVA vaccines was verified in vitro. Five RMs were inoculated with two DNA, followed by two MVA, and finally with two gp140 Env vaccines at weeks 0, 4, 8, 12, 20 and 28. Vaccine-induced T cell immunity was measured by IFN-γ ELISpot while nAbs were evaluated against MW965 (Tier 1A), 6644 (Tier 1B), autologous ZM109.5A and a closely-related ZM109.B4 (Tier 2) pseudovirions. Vaccinated RMs were challenged intrarectally with simian-human immunodeficiency virus (SHIV), four weeks after the final vaccination, as was an unvaccinated control group (n = 4). Following vaccination, all the animals developed moderate IFN-γ ELISpot responses after the DNA vaccinations which were boosted by the MVA vaccine. After the gp140 Env boost, all animals developed nAbs with peak median titres at 762 (MW965) and 263 (ZM109.5A). The vaccinated animals became infected after a similar number of challenges to the unvaccinated controls, and the resultant number of viral copies in the blood and the lymphoid tissues were similar. However, the duration of detectable viraemia in the vaccinated animals (median: 2 weeks) was shorter than the controls (median: 8.5 weeks). These data show that the vaccines elicited robust cellular and functional humoral immune responses that resulted in a quicker control of viraemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Primate Unit and Delft Animal Centre, Centre and Platform Office, South African Medical Research Council, Parrow Valley, Cape Town 7505, South Africa.
- Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
- SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2000, South Africa.
- National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg 2192, South Africa.
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban 4001, South Africa.
ORCID-Profile: Gerald K Chege, Rosamund E Chapman, Michiel T van Diepen, Nicola Douglass, Penny L Moore, Anna-Lise Williamson
Förderung
- South African Medical Research Council with funds received from the South African Department of Science and Innovation. PLM is supported by the South African R…
- South African Medical Research Council
- South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation
Zitieren
APA
Chege, G. K., Chapman, R. E., Keyser, A. T., Adams, C. H., Benn, K., van Diepen, M. T., Douglass, N., Lambson, B., Hermanus, T., Moore, P. L., & Williamson, A. L. (2025). Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge. Viruses, 17(2), 277. https://doi.org/10.3390/v17020277
Vancouver
Chege GK, Chapman RE, Keyser AT, Adams CH, Benn K, van Diepen MT, et al. Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge. Viruses. 2025;17(2):277. doi:10.3390/v17020277
BibTeX
@article{Chege2025,
author = {Chege, Gerald K and Chapman, Rosamund E and Keyser, Alana T and Adams, Craig H and Benn, Kealan and van Diepen, Michiel T and Douglass, Nicola and Lambson, Bronwen and Hermanus, Tandile and Moore, Penny L and Williamson, Anna-Lise},
title = {Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge},
journal = {Viruses},
year = {2025},
volume = {17},
number = {2},
pages = {277},
doi = {10.3390/v17020277}
}
EUVIMED